Filing Flows › Solesence (SLSN) › Q1 2026 › vs Q1 2025
Solesence (SLSN) Q1 2026 vs Q1 2025 (year over year)
Solesence's revenue fell $1.7M (-11%) from $14.6M in Q1 2025 to $13.0M in Q1 2026. The biggest changes: Product −$1.7M (-11%); Product and Service, Other −$12K (-24%).
Solesence, Q1 2026: revenue $13.0M (-11% year over year), operating margin -3.9%, net loss $766K, operating cash flow $1.5M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Consumer Products | $10.0M | $12.9M | −$2.9M | -22% |
| Personal Care ingredients | $2.7M | $1.4M | $1.4M | +98% |
| Advanced Materials | $205K | $370K | −$165K | -45% |
| Product | $13.0M | $14.6M | −$1.7M | -11% |
| Product and Service, Other | $38K | $50K | −$12K | -24% |
| Revenue | $13.0M | $14.6M | −$1.7M | -11% |
| Net loss | $766K | −$80K | $846K | — |
| Costs & expenses | $13.7M | $14.6M | −$902K | -6% |
| Operating costs | $13.5M | $14.4M | −$908K | -6% |
| Interest & other, net | $262K | $176K | $86K | +49% |
| Cost of revenue | $9.6M | $11.2M | −$1.6M | -14% |
| Research & development | $1.0M | $1.0M | $24K | +2% |
| SG&A | $2.8M | $2.1M | $691K | +33% |
| Operating cash sources | $2.3M | −$7.3M | $9.6M | — |
| Depreciation & amortization | $313K | $226K | $87K | +38% |
| Share-based compensation | $83K | $127K | −$44K | -35% |
| Working capital & other | $1.9M | −$7.7M | $9.5M | — |
| Net loss absorbed | $766K | −$80K | $846K | — |
| Operating cash flow | $1.5M | −$7.2M | $8.7M | — |
Questions
How much did Solesence's revenue grow year over year in Q1 2026?
Solesence's revenue fell $1.7M (-11%) from $14.6M in Q1 2025 to $13.0M in Q1 2026.
What drove Solesence's revenue change in Q1 2026?
Product −$1.7M (-11%); Product and Service, Other −$12K (-24%).